Braxia Scientific Corp.

Equities

BRAX

CA1057361026

Healthcare Facilities & Services

Market Closed - Canadian Securities Exchange Other stock markets 07:00:00 07/06/2024 pm IST			5-day change	1st Jan Change
0.005 ^CAD	0.00%		0.00%	-50.00%

29/02	Braxia Scientific Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Braxia Scientific Corp. Announces Board Changes	CI

In Toronto Braxia Scientific Corp. Works to Expand Capacity

August 30, 2022 at 03:15 am IST

In Toronto Braxia Scientific Corp. is working to expand capacity to support increased volumes for in-person ketamine treatments, and as the research team prepares to launch new clinical trials before the end of 2022.

Latest news about Braxia Scientific Corp.

Braxia Scientific Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	01/03	CI
Braxia Scientific Corp. Announces Board Changes	30/11	CI
Braxia Scientific Corp. Announces CFO Changes	30/11	CI
Braxia Scientific Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	29/11	CI
Braxia Scientific Corp. Reports Earnings Results for the First Quarter Ended June 30, 2023	29/23/29	CI
Braxia Scientific Corp. Reports Earnings Results for the Full Year Ended March 31, 2023	31/23/31	CI
Braxia Scientific Provides Operations Update	09/23/09	MT
Irwin Naturals Launches New Product in Canada	24/23/24	MT
Irwin Naturals Brief: Says Cannabis Products Launch Nationwide in Canada	24/23/24	MT
Irwin Naturals Closes Purchase of Ketamine Media	22/23/22	MT
Irwin Naturals Brief: CEO of Irwin Naturals, Klee Irwin, Expressed Disappointment on the Announcement, But Recognized the Decision was "Based on a Lack of a Clear Business Rationale for the Company to move forward with the Transaction"	16/23/16	MT
Irwin Naturals Brief: Says has terminated Non-binding amended and restated letter of intent for a business combination with Braxia Scientific Corp.	16/23/16	MT
Irwin Naturals Inc. cancelled the acquisition of Braxia Scientific Corp..	16/23/16	CI
Braxia Scientific Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	01/23/01	CI
Braxia Scientific Corp. announced that it has received CAD 0.513 million in funding	27/23/27	CI
Irwin Naturals Closes Purchase of Kentucky Clinic	21/23/21	MT
Braxia Scientific Corp. announced that it expects to receive CAD 1.5 million in funding	07/23/07	CI
Refile: Irwin Naturals Secures Credit Facility For Up To US$60 Million	02/23/02	MT
Irwin Naturals Brief: Says Secured US$40 Million of Financing for its Current Operations including Psychedelic Mental Health Clinic Rollup, Potential for up to $60 Million	02/23/02	MT
Irwin Naturals Brief: Says Signed Letter of Intent to Acquire Braxia Scientific	30/23/30	MT
Irwin Naturals Reports Letter of Intent to Purchase Braxia Scientific	27/23/27	MT
Irwin Naturals Brief: And a deemed value per subordinate voting share and/or proportionate voting share of Irwin equal to the greater of US$3.00 and the volume weighted average trading price of Irwin Shares on the CSE	27/23/27	MT
Irwin Naturals Brief: Under the terms of the LOI, Irwin Prepared to Offer a purchase price per Braxia Share based upon a valuation of the outstanding Braxia Shares of US$30 Million	27/23/27	MT
Irwin Naturals Brief: Signing Letter of Intent to Acquire Braxia Scientific	27/23/27	MT
Irwin Naturals Inc. signed letter of intent to acquire Braxia Scientific Corp. for CAD 39.9 million.	27/23/27	CI

Chart Braxia Scientific Corp.

Duration

Period

More charts

Company Profile

Braxia Scientific Corp. is a Canada-based company, which is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing drugs and delivery methods. The Company seeks to develop ketamine and derivatives and other psychedelic products from its Internet protocol (IP) development platform. The Company has clinic operations in the Canadian cities of Mississauga, Toronto, Kitchener-Waterloo, Ottawa and Montreal. The Company, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., it operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, Kitchener and Montreal. Its subsidiaries include Altmed Capital Corp., Artisan Growers Ltd., KetaMD, Inc., Novo Formulations Ltd. and Tassili Life Sciences Corp.

Sector

Healthcare Facilities & Services

Calendar

29/07/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
BRAXIA SCIENTIFIC CORP.	-50.00%	10.35L
HCA HEALTHCARE, INC.	+24.66%	8.82TCr
CVS HEALTH CORPORATION	-21.76%	7.65TCr
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+1.76%	2.7TCr
FRESENIUS SE & CO. KGAA	+7.94%	1.86TCr
LABCORP HOLDINGS INC.	-13.50%	1.67TCr
QUEST DIAGNOSTICS INCORPORATED	+3.23%	1.58TCr
NATERA, INC.	+77.51%	1.34TCr
TENET HEALTHCARE CORPORATION	+76.96%	1.32TCr
UNIVERSAL HEALTH SERVICES, INC.	+23.02%	1.27TCr

Other Healthcare Facilities & Services